Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan.
Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan.
Heart Lung Circ. 2023 Feb;32(2):205-214. doi: 10.1016/j.hlc.2022.09.007. Epub 2022 Oct 20.
Coexisting sick sinus syndrome (SSS) is associated with both electrical and structural atrial remodelling in patients with atrial fibrillation (AF). Limited data are available concerning catheter ablation (CA) for AF in this condition. This study investigated the efficacy of CA as a curative therapy for AF and SSS in a large-scale prospective multicentre registry.
The Kansai Plus Atrial Fibrillation (KPAF) registry enrolled 5,010 consecutive patients who underwent CA for AF; this included 3,133 patients with paroxysmal AF (mean age, 66 years; male, 69.3%; mean CHADS-VASc score, 2.05±1.50; SSS, n=315 [tachy-brady syndrome, n=285]). The endpoints included the recurrence of AF with a blanking period of 90 days after CA, and de novo pacemaker implantation during the follow-up period (median duration, 2.93 years).
The AF-free survival did not significantly differ between patients with and those without SSS (n=2,818) after the initial (log-rank p=0.864) and final sessions (log-rank p=0.268). Pacemakers were implanted in 48 patients with SSS, and implantation in this group was significantly associated with AF recurrence, including early recurrence (adjusted odds ratio, 3.57; 95% confidence interval, 1.67-7.64; p=0.002). The remaining 85.3% of patients with SSS did not require pacemaker implantation at 3 years after CA.
Coexisting SSS did not adversely affect recurrence-free survival after CA for paroxysmal AF. Pacemaker implantation was not required in most patients with SSS, with AF recurrence serving as a strong predictor for this.
共存病态窦房结综合征(SSS)与心房颤动(AF)患者的电和结构心房重构有关。关于这种情况下 AF 的导管消融(CA),可用的数据有限。本研究通过一项大型前瞻性多中心注册研究,调查了 CA 作为 AF 和 SSS 根治性治疗的疗效。
关西加 AF (KPAF) 注册研究纳入了 5010 例连续接受 CA 治疗的 AF 患者;其中包括 3133 例阵发性 AF 患者(平均年龄 66 岁;男性 69.3%;平均 CHADS-VASc 评分 2.05±1.50;SSS 患者 315 例[心动过速-心动过缓综合征患者 285 例])。终点包括 CA 后 90 天空白期 AF 复发和随访期间新植入起搏器。(中位随访时间 2.93 年)。
在初始(log-rank p=0.864)和最终(log-rank p=0.268)治疗后,有和无 SSS 的患者之间的 AF 无复发生存时间无显著差异(n=2818)。SSS 患者中有 48 例植入了起搏器,并且该组的起搏器植入与 AF 复发显著相关,包括早期复发(调整后的优势比,3.57;95%置信区间,1.67-7.64;p=0.002)。CA 后 3 年,其余 85.3%的 SSS 患者无需植入起搏器。
共存 SSS 不会对阵发性 AF 的 CA 后无复发生存时间产生不利影响。大多数 SSS 患者无需植入起搏器,AF 复发是其重要预测因素。